BofA raised the firm’s price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm’s higher target reflects a higher P/E multiple given recent moves in peer ...

Khloé Kardashian made a bold diagnosis for her sister Kim on the latest episode of Hulu's The Kardashians.

Call him Dr. Sleep. David A. Cohen, MD, is the Section Chief of Sleep Medicine for St. Luke’s. A trip to the sleep doctor can ...

RBC Capital initiated coverage of Alkermes (ALKS) with a Sector Perform rating and $40 price target The company’s next-generation orexin has a ...

One woman shares about the narcolepsy symptoms that disrupted her life, and the journey to a diagnosis: "I'm living proof you ...

An expert discusses considerations for tailoring narcolepsy treatment plans for patients with complex comorbidities or ...

Limited or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' ...

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, ...

Trey then tackled one of his toughest challenges in life: a diagnosis of narcolepsy. "I would kind of question myself. I love basketball. But I can get on the bench and, like, I start yawning ...

UBS analyst Ashwani Verma upgraded Alkermes (ALKS) to Neutral from Sell with a price target of $38, up from $21. UBS has more confidence in ...

In the 10-K report, Avadel Pharmaceuticals highlighted key financial and operational metrics. For the year ended December 31, ...

NLS Pharmaceutics Ltd., in collaboration with Aexon Labs Inc., has announced new preclinical findings on AEX-2, a non-sulfonamide dual orexin receptor agonist (DOXA) with potential for narcolepsy and ...